Cleveland BioLabs, Inc. (CBLI) Receives an Increase in DoD Protectan CBLB502 Contract
More News related to CBLI
- Cleveland BioLabs (CBLI) Gets Patent for Radiation Protection, Including Protectan CBLB502
- Cleveland BioLabs Granted European Patent for Radiation Protection Drug CBLB502
- Cleveland BioLabs to Present at 12th Annual BIO CEO & Investor Conference
- Cleveland BioLabs Doses First Volunteers in Second Safety Study for CBLB502
- Cleveland BioLabs to Respond to Department of Defense Request for Proposal for Radiation Countermeasure
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Cleveland BioLabs, Inc. (Nasdaq: CBLI) announced today that the Chemical Biological Medical Systems Medical Identification and Treatment Systems Joint Program Executive Office (CBMS-MITS JPEO) of The Department of Defense (DoD) incresed the ongoing contract for the developmental studies related to Protectan CBLB502. The contract, awarded in April 2008, will increase from $8.86 million to $9.59 million.
Related Categories
Corporate NewsStocks Mentioned
-0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
